StockNews.com Upgrades ICU Medical (NASDAQ:ICUI) to “Buy”

ICU Medical (NASDAQ:ICUI) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

ICUI has been the topic of a number of other reports. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target on the stock in a report on Wednesday, December 11th. Raymond James set a $97.00 target price on shares of ICU Medical in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $168.67.

ICU Medical Stock Up 2.1 %

NASDAQ:ICUI opened at $151.25 on Tuesday. ICU Medical has a fifty-two week low of $93.36 and a fifty-two week high of $196.26. The stock has a market capitalization of $3.71 billion, a P/E ratio of -33.10 and a beta of 0.73. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The company’s 50-day simple moving average is $156.48 and its 200-day simple moving average is $164.65.

Insider Buying and Selling

In related news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.48, for a total value of $213,474.04. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. The trade was a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ICU Medical

A number of large investors have recently modified their holdings of ICUI. Atria Investments Inc purchased a new stake in shares of ICU Medical during the third quarter worth $228,000. CIBC Asset Management Inc grew its holdings in shares of ICU Medical by 9.8% during the third quarter. CIBC Asset Management Inc now owns 2,262 shares of the medical instruments supplier’s stock worth $412,000 after buying an additional 201 shares in the last quarter. Mutual of America Capital Management LLC grew its holdings in shares of ICU Medical by 9.2% during the third quarter. Mutual of America Capital Management LLC now owns 3,673 shares of the medical instruments supplier’s stock worth $669,000 after buying an additional 308 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of ICU Medical by 12.9% during the third quarter. Thrivent Financial for Lutherans now owns 19,181 shares of the medical instruments supplier’s stock worth $3,495,000 after buying an additional 2,190 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of ICU Medical by 5.6% during the third quarter. Swiss National Bank now owns 45,219 shares of the medical instruments supplier’s stock worth $8,240,000 after buying an additional 2,400 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.